In 750 high/extreme surgical risk patients with severe aortic stenosis, the intra-annular Portico TAVR valve gave similar 5-year death or stroke vs commercial valves (55.6% vs 51.3%, P=0.42), but more new pacemakers (36.6% vs 20.3%).
RCTn = 750
Makkar et al. 5-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves